Our Blog

Clear All Filters

February 09, 2024 | The American Prospect

Max Moran

Op-Ed Congressional OversightEthics in GovernmentJudiciarySupreme Court

Durbin Must Enforce His SCOTUS Investigation Subpoenas

Uncovering Crow’s and Leo’s full relationships with the Court is precisely the sort of scenario for which Congress has subpoena powers in the first place. As of now, these plutocrats have been able to scoff at the will of elected leaders. Durbin’s actions, or lack thereof, will inform whether history remembers this Congress as stepping up or shrugging off one of the greatest threats to the American legal system in our lifetimes.

February 08, 2024

KJ Boyle Toni Aguilar Rosenthal

Blog Post Ethics in GovernmentFederal ReserveFOIA

The Fed's FOIA Office Is Obscuring Its Trading Scandals

In October of 2021, the Federal Reserve was embroiled in scandal. The heads of the Boston and Dallas Feds resigned following personal trading scandals that raised concerns about conflicts of interest and lax ethics guidelines. Further reports of potentially inappropriate trading by Chair Jerome Powell and Vice Chair Clarida rocketed across the business media due to these officials’ immense access to sensitive financial information and influence on monetary policy. Despite their decidedly questionable profiteering off pandemic panic, Powell and Clarida have since had their reputations effectively laundered by the media in a whitewashing effort that has attempted to clear them of all wrongdoing. To make matters worse, the Fed’s FOIA office is doing everything in its power to prevent internal documents relating to the scandals from reaching the light of day.

February 06, 2024

Timi Iwayemi

Public Comment

Department of CommerceExecutive BranchHealthPharma

Civil Society Comment on the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Unfortunately, despite numerous petitions presented over the 40-plus year history of the Bayh-Dole Act, not once has a federal agency exercised its right to march-in and license competition to remedy price gouging (which constitutes a failure of the owner of a subject invention to make that invention available to the public on reasonable terms), or otherwise.

January 31, 2024 | Revolving Door Project Newsletter

KJ Boyle

Newsletter Anti-MonopolyExecutive BranchIndependent AgenciesLaborRevolving Door

More Revolvers Join The Fight Against The Regulatory State

The regulatory authority of the executive branch is under attack, and BigLaw firms stacked with revolvers are on the front lines leading the assault. I’ve previously written about former FTC Commissioner Christine Varney challenging the legitimacy of her former employer on behalf of pharma company Illumina. Lawyers at Latham & Watkins, a firm stacked with revolvers from executive branch agencies, are before the Supreme Court challenging the Chevron Doctrine, which defers to executive agencies’ interpretations when legislative statutes are unclear. The Securities and Exchange Commission’s ability to hold administrative proceedings hangs in the balance as we await the Supreme Court’s decision in SEC v. Jarkesy, where the Fifth Circuit’s ruling decimated the agency’s authority. In a new attack, revolvers on the labor/management relations team at Morgan Lewis & Bockius have their sights set on the plutocrats’ latest target: the National Labor Relations Board.

January 26, 2024

KJ Boyle

Blog Post Anti-MonopolyFTCPharma

The FTC Ain’t Nothin to Mess With

The FTC has won its lawsuit against Martin Shkreli, the pharmaceutical executive infamous for jacking up the price of the antiparasitic drug Daraprim from $13.50 to $750 overnight in 2015 and later using his ill-gotten fortune to buy an exclusive Wu-Tang Clan album for $2 million. Shkreli is the quintessential corporate ghoul, having already racked up convictions for securities fraud—which resulted in an indefinite ban from the securities industries—and failure to pay $1.26 million in New York state taxes. Now, his price gouging has finally caught up with him, as the FTC successfully argued that he spearheaded an anti-competitive scheme to monopolize the drug. The presiding judge found Shkreli’s conduct to be “egregious, deliberate, repetitive, long-running, and ultimately dangerous,” issuing a $64.6 million fine and imposing a lifetime ban from the pharmaceutical industry. 

January 26, 2024 | The American Prospect

Timi Iwayemi

Op-Ed AccountingAnti-MonopolyEthics in GovernmentFinancial RegulationRevolving Door

Corporate Self-Oversight

Accounting’s technical jargon makes the industry obscure to most Americans. It’s likely your next-door neighbor has no idea of the PCAOB’s activities, its responsibility to protect investors, or its history of negligence. That’s expected, but chair Williams is now working to turn the ship around to fix the shortcomings of one of America’s most consequential oligopolies, and it will improve the economic lives of an unaware public.